Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Completed 6Recruiting 5Terminated 4Withdrawn 2Active not recruiting 2Unknown 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5Thoracic 1Other solid neoplasm 1Lymphoid 1Gynecologic 1

Conditions

Prostatic Neoplasms 35Prostatic Neoplasms, Castration-Resistant 5Neoplasm Metastasis 5Metastatic Castration-Resistant Prostate Cancer 4Neoplasms 3Small Cell Lung Carcinoma 2Prostatic Diseases 2Prostate Adenocarcinoma 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sleep Initiation and Maintenance Disorders 1Recurrence 1Prostate Cancer Metastatic 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Neoadjuvant Therapy 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate-Resistant Prostate Cancer 1Mesothelioma, Malignant 1Melanoma 1

Interventions

enzalutamide 5darolutamide 4Docetaxel 3Prednisone 2olaparib 1gedatolisib 1fludrocortisone acetate 1cabazitaxel 1abiraterone 1TVB-2640 1Radiosurgery 1Omeprazole 1Dexamethasone 1Androgen Antagonists 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Prostatic Neoplasms, Castration-Resistant × enzalutamide × Clear all
NCT06863272 2026-05-15

IDeate-Prostate02

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
360 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT05997615 2026-04-20

AMX-500

Vir Biotechnology, Inc.

Phase 1 Recruiting
390 enrolled
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05743621 2025-11-21

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

Weill Medical College of Cornell University

Phase 1 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis

Phase 1/2 Recruiting
275 enrolled
GenitourinaryGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05393791 2024-11-26

ANZadapt

Leiden University Medical Center

Phase 2 Recruiting
168 enrolled
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡